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Abstract
We aimed to investigate the clinical significance of the expression of novel scaffold protein CARMA3 in non-small-cell lung
cancer (NSCLC) and the biological function of CARMA3 in NSCLC cell lines. We observed moderate to high CARMA3 staining
in 68.8% of 141 NSCLC specimens compared to corresponding normal tissues. The overexpression of CARMA3 was
significantly correlated with TNM stage (P=0.022) and tumor status (P=0.013). CARMA3 upregulation also correlated with a
shorter survival rate of patients of nodal status N0 (P=0.042)as well as the expression of epidermal growth factor receptor
(EGFR) (P=0.009). In EGFR mutation positive cases, CARMA3 expression was much higher (87.5%) compared to non-
mutation cases (66.1%). In addition, we observed that knockdown of CARMA3 inhibits tumor cell proliferation and invasion,
and induces cell cycle arrest at the boundary between the G1 and S phase. We further demonstrated a direct link between
CARMA3 and NF-kB activation. The change of biological behavior in CARMA3 knockdown cells may be NF-kB-related. Our
findings demonstrated, for the first time, that CARMA3 was overexpressed in NSCLC and correlated with lung cancer
progression, EGFR expression, and EGFR mutation. CARMA3 could serve as a potential companion drug target, along with
NF-kB and EGFR in EGFR-mutant lung cancers.
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Introduction
CARMA3 (also known as CARD10 or Bimp1) belongs to the
CARMA family and contains three members, CARMA1 (also
known as CARD11), CARMA2 (CARD14), and CARMA3.
These three proteins share similar structural motifs, contain a
CARD domain, a Src-homology 3 (SH3) domain, one or several
PDZ domains, and a GuK domain. However, they exhibit distinct
expression profiles; CARMA1 is expressed in hematopoietic cells,
CARMA2 in the placenta, and CARMA3 in all non-hematopoi-
etic cells [1–4]. Recent studies have demonstrated that CARMA3,
as a scaffold protein, plays a critical role in GPCR ligands and
PKC-induced NF-kB activation [5–8]. It has been previously
demonstrated that NF-kB activation is involved in tumorigenesis
and in the development of neural, heart, and immune diseases [9–
13]. CARMA3 activates NF-kB by recruiting Bcl10 and MALT1,
two indispensable proteins that are required for GPCR and PKC-
induced NF-kB activation [6,14–16]. The PKCa-CARMA3
signaling axis plays an essential role in LPA-induced ovarian
cancer cell in vitro invasion [17]. A recent study demonstrated that
CARMA3 deficiency impaired cancer cell proliferation in vitro
and in vivo, and inhibited survival, migration, and invasion in
human breast cancer cell lines MDA468 and A431 [18].
CARMA3 knockdown caused marked inhibition of SDF-1a
mediated invasion of oral squamous cell carcinoma TB2–T4 cells
[7]. However, the protein expression of CARMA3 in lung cancer
tissues and the potential role of CARMA3 in the biological
behavior of lung cancer cells have not been explored. Thus, we
examined the expression of CARMA3 in lung cancer tissues and
its relationship with various clinicopathological parameters. In
addition, we assessed the association of CARMA3 expression with
the proliferation and metastatic potential of several NSCLC cell
lines.
Materials and Methods
Patients and Specimens
This study was approved by the Ethics Committee of the China
Medical University, and written informed consent was obtained
from each patient. 141 cases of NSCLC samples were obtained
form the First Affiliated Hospital of China Medical University
during the period of 2008 to 2011. The histological diagnosis and
grade of differentiation of the tumors were defined by evaluation
of the hematoxylin and eosin-stained tissue sections, according to
the World Health Organization guidelines of classification. All 141
specimens were re-evaluated with respect to their histological
subtypes, differentiation status, and tumor stages. For NSCLC
samples, SCC and adenocarcinoma were identified in 65 and 76 of
the 141 cases, respectively. Lymph node metastases were observed
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36903in 68 of the 141 patients. The p-TNM taging system of the
International Union Against Cancer (7th Edition) was used to
classify specimens as stages I (n=64), II (n=41), III (n=30) and
IV (n=6).
Cell Lines
A549,H1299,HBE and H460 were obtained from American
Type Culture Collection (Manassas, VA, USA), LK2 was obtained
from the Japanese Cancer Research Resources Bank (Tokyo,Ja-
pan),SPC were obtained from CCTCC (Chinese Center of
Typical Culture Conserve, Wuhan, P.R.China), H157 was
purchased from Cell Bank, Chinese Academy of Sciences
(Shanghai, China), The BE1 and LH7 were gifts from Dr. Jie
Zheng (College of Medicine, Beijing University, China).The cells
were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA)
containing 10% fetal calf serum (Invitrogen), 100 IU/ml penicillin
(Sigma, St. Louis, MO, USA), and 100 mg/ml streptomycin
(Sigma). Cells were grown on sterile tissue culture dishes and were
passaged every 2 days using 0.25% trypsin (Invitrogen).
Immunohistochemistry
Surgically excised tumor specimens were fixed with 10% neutral
formalin, embedded in paraffin and 4 mm thick sections were
prepared. Immunostaining was performed using the avidin–
biotin–peroxidase complex method (Ultra Sensitive TM, Maixin,
Fuzhou, China). The sections were deparaffinized in xylene,
rehydrated in graded alcohol series and boiled in 0.01 M citrate
buffer (pH 6.0) for 2 minutes in an autoclave. Endogenous
peroxidase activity was blocked using hydrogen peroxide (0.3%),
which was followed by incubation with normal goat serum to
reduce non-specific binding. Tissue sections were incubated with
CARMA3 rabbit polyclonal antibody (1:80 dilution) (Sigma).
Mouse immunoglobulin (at the same concentration of the antigen
specific antibody) (Maixin, Fuzhou, China) was used as a negative
control. Staining for all primary antibodies was performed at room
temperature for 2 hours. HRP-Polymer Conjugated anti Mouse/
Rabbit IgG (ready-to-use ) (Maixin, Fuzhou, China) was used as
the secondary antibody. After washing, the sections were
incubated with horseradish peroxidase-conjugated streptavidin–
biotin, followed by 3, 39-diaminobenzidine tetrahydrochloride to
develop the peroxidase reaction. Counterstaining of the sections
was done with hematoxylin, which were then dehydrated in
ethanol before mounting.Two independent investigators examined
all tumor slides randomly. Five views were examined per slide, and
100 cells were observed per view at 4006magnification. Normal
bronchial epithelium present in the tumor sections was used as
negative control. Immunostaining of CARMA3 was scored
following a semi-quantitative scale by evaluating in representative
tumor areas, the intensity and percentage of cells showing higher
immunostaining than the control cells. cytoplasmic staining of the
tumor cells was considered as positive immunostaining. The
intensity of CARMA3 cytoplasmic staining was also scored as 0
(no staining), 1 (weak), 2 (marked). Percentage scores were assigned
as 1- 1–25%, 2- 26–50%and 3- 51–100%. The scores of each
tumor sample were multiplied to give a final score of 0 to 6 and the
total expression of CARMA3 was determined as either negative or
low expression (-): score ,3 or positive expression or high
expression (+): score $3.
Analysis of EGFR Mutation
Paraffin sections of 75 NSCLC specimens for EGFR mutation
analysis were obtained from First Affiliated Hospital of China
Medical University between 2009 and 2011. Briefly, DNA was
extracted from paraffin-embedded tissue sections using TaKaRa
DEXPAT Easy Kit (TAKARA Biotechnology, Dalian, China)
according to the manufacturer’s protocol. EGFR mutations were
detected using EGFR mutation detection kit (GP Medical
Technologies, Beijing, China) on 7900HT Fast Real-Time PCR
System (Applied Biosystems,Foster City,Calif).
Quantitative Real-time PCR (SYBR Green Method)
Quantitative real-time PCR was performed using SYBR Green
PCR master mix (Applied Biosystems) in a total volume of 20 ml
on 7900HT Fast Real-Time PCR System (Applied Biosystems) as
follows: 95uC for 30 seconds, 40 cycles of 95uC for 5 seconds, 60uC
for 30 seconds. A dissociation step was performed to generate a
melting curve to confirm the specificity of the amplification. b-
actin was used as the reference gene. The relative levels of gene
expression were represented as DCt=Ct gene –Ct reference, and
the fold change of gene expression was calculated by the 2-DDCt
method. The primer sequences are provided in Table S1,
Experiments were repeated in triplicate.
Western Blot Analysis
Total proteins from primary tissues and cell lines were extracted
in lysis buffer (Thermo Fisher Scientific,Rockford,IL) and quan-
tified using the Bradford method. Fifty micrograms of protein were
separated by SDS–PAGE (12%). After transferring, the poly-
vinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA,
USA) were incubated overnight at 4uC with the following
antibodies CARMA3(1:200; Sigma), Bcl-10 and b-actin (1:500;
Santa Cruz Biotechnology, Santa Cruz,CA),anti-phospho-ERK,
anti-phospho-IKK,anti-phospho-IkB, anti-phospho-Rb,anti-P27,
anti-Cyclin A, anti-Cyclin D1, anti-Cyclin D3, anti-CDK4 and
anti-CDK6(1:1000; Cell Signaling Technology,Danvers,MA).
After incubation with peroxidase-coupled anti-mouse or rabbit
IgG (Santa Cruz Biotechnology) at 37uC for 2 hours, bound
proteins were visualized using ECL (Thermo Fisher Scientific) and
detected using BioImaging Systems (UVP Inc., Upland, CA,
USA). The relative protein levels were calculated based on b-actin
as the loading control.
Small Interfering RNA Treatment
Dharmacon siGENOME SMARTpool siRNA for CAR-
MA3,Bcl10 and Dharmacon siGENOME Non-targeting siRNA
#1 were purchased from Dharmacon (ThermoFisher Scientific).
For transfections, cells were seeded in a 24-well plate 24 h before
the experiment. The cells were transfected with siRNA using the
DharmaFECT 4 (0.20 mL/well; ThermoFisher Scientific) accord-
ing to the manufacturer’s protocol. Following transfection, the
mRNA and protein levels were assessed 48 hours later.
Cell Proliferation Test
Cell proliferation assay was performed using Cell Counting Kit-
8H solution (Dojindo, Gaithersburg, MD) according to the
manufacturer’s protocol. Briefly, cells were seeded at a concen-
tration of 5610
3 cells/100 ml/well in 96-well culture plates and
treated with 10 ml/well of Cell Counting Kit-8H solution during
the last 4 hours of the culture. Optical density of the wells was
measured at 450 nm using a microplate reader.
Colony Formation Assay
For colony formation assays, cells were grown on 6 cm dishes at
a density of 5,000 cells/dish, and transfected with CARMA3,
Bcl10, or negative control siRNAs. Colonies were washed twice
with PBS, fixed, and stained with formaldehyde-crystal violet 13–
CARMA3 in NSCLC
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repeated a minimum of three times under identical conditions.
Matrigel Invasion Assay
Cell invasion assay was performed using a 24-well Transwell
chamber with a pore size of 8 mm (Costar,Cambridge,MA). The
inserts were coated with 20 ml Matrigel (1:3 dilution, BD
Bioscience, San Jose, CA,USA). Forty-eight hours after the
transfection, cells were trypsinized and 3610
5 cells in 100 mlo f
serum-free medium were transferred to the upper Matrigel
chamber and incubated for 16 hours. After incubation, the non-
invaded cells on the upper membrane surface were removed with
a cotton tip, and the cells that passed through the filter were fixed
with 4% paraformaldehyde and stained with hematoxylin. The
number of invaded cells was counted in 10 randomly selected high
power fields under the microscope. This experiment was
performed in triplicate.
Cell Cycle Analysis
Cells (500,000) were seeded into 6-cm tissue culture dishes.
After 12 h of incubation, cells were transfected with indicated
amounts of siRNA. Cells were fixed with 75% ethanol 48 h after
transfection, washed with phosphate-buffered saline (PBS), and
stained in 5 mg/ml propidium iodide in PBS supplemented with
Figure 1. Immunohistochemical staining of CARMA3 in lung cancer tissue sections. (A) Strong CARMA3 expression in lung
adenocarcinoma(4006). (B) Weak CARMA3 expression in lung adenocarcinoma(4006). (C) Strong CARMA3 expression in lung squamous cell
carcinoma(4006). (D) Weak CARMA3 expression in lung squamous cell carcinoma(4006). (E) Normal bronchial epithelium showing weak staining for
CARMA3(4006). (F) Negative controls for CARMA3 staining with non-immune mouse IgG antibody(4006).
doi:10.1371/journal.pone.0036903.g001
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temperature. Data were collected using BD systems.
Luciferase Assay
Cells were initially transfected with CARMA3, Bcl10, or
negative control siRNAs for 24 h; cells were then co-transfected
with 500 ng pNF-kB-Luc reporter plasmid, and 100 ng Renilla
luciferase plasmid for 24 h. The cells were treated for 30 min with
or without EGF (100 ng/ml), and then lysed; luciferase activity
was determined with a dual-luciferase reporter assay system
(Promega, Madison, WI, USA) according to the manufacturer’s
instructions. NF-kB activity was assessed upon normalization of
firefly luciferase activity to Renilla luciferase activity. Experiments
were performed in triplicate in three independent experiments.
Statistical Analysis
SPSS version 16.0 for Windows was used for all analyses. The
Chi-squared test was used to examine possible correlations
between CARMA3 expression and clinicopathologic factors.
Kaplan–Meier curves were used for survival analysis, and log-
rank was determined based on the differences. The Student’s t-test
was used to compare other data. p-values were based on the two-
sided statistical analysis, and p,0.05 was considered to indicate
statistical significance.
Results
Clinical Significance of CARMA3 Protein Expression in
NSCLC Tissues
We analyzed the protein expression levels of CARMA3 using
immunohistochemistry of 91 NSCLC specimens and their
corresponding normal tissues. CARMA3 was found to be
predominately expressed in the cytoplasmic compartment. Normal
bronchial epithelia exhibited negative or weak CARMA3 staining
(Fig. 1E), whereas CARMA3 staining was significantly stronger in
lung cancer tissues. We found moderate to high CARMA3
staining in 69% of the lung cancer specimens (Fig. 1A and C). We
also use western-blotting to analyze the expression of CARMA3 in
18 cases.The results show that 56% of the lung cancer specimens
show moderate to high CARMA3 expression (Figure S2, S3).
The correlation between CARMA3 expression and the
clinicopathologicfactors of NSCLC is shown in Table 1.
CARMA3 overexpression exhibited a significant correlation with
TNM stage (P=0.022) and tumor status (P=0.013), but no
correlation was observed concerning age, sex, differentiation,
lymph node metastases, and tumor histology. To better claim the
correlation of CARMA3 with lung cancer progression, we
evaluated the relationship between the expression of CARMA3
and overall survival of N0 stage NSCLC patients(38 CAMRA3+
and 16 CAMRA3 - ). After Kaplan-Meier survival analysis, we
found that patients with low expression of CARMA3 had a
statistically significant longer survival(median survival=3263.80
months; 95% confidence interval 24.56–39.44 months) than those
Table 1. Distribution of CARMA3 status in NSCLC according to clinicopathological characteristics.
Characteristics patients CARMA3 positive CARMA3 negative P
Age
,60 74 49(66.22%) 25(33.78%) 0.305
$60 67 48(71.64%) 19(28.36%)
Gender
Male 83 53(63.86%) 30(36.14%) 0.091
Female 58 44(75.86%) 14(24.14%)
Histology
Adenocarcinoma 76 57(75.00%) 19(25.00%) 0.062
Squamous cell carcinoma 65 40(61.54%) 25(38.46%)
Differentiation
Well 63 43(68.25%) 20(31.75%) 0.522
Moderate- Poor 78 54(69.23%) 24(30.77%)
TNM stage
I 64 38(59.38%) 26(40.63%) 0.022
II+III+IV 77 59(76.62%) 18(23.38%)
Tumor status
T1–T2 75 45(60.00%) 3040.00%) 0.013
T3–T4 66 52(78.79%) 14(21.21%)
Nodal status
N0 73 46(63.01%) 27(36.99%) 0.088
N1 N2 N3 68 51(75.00%) 17(25.00%)
EGFR status
Negative 61 35(57.38%) 26(42.62%) 0.009
Positive 80 62(77.50%) 18(22.50%)
doi:10.1371/journal.pone.0036903.t001
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months; 95% confidence interval 12.33–27.67 months; P=0.042;
Figure S4).
A recently reported study demonstrated that CARMA3
expression is required for EGFR induced NF-kB activation [15].
EGFR overexpression has been demonstrated in many human
cancers, including lung, colon, pancreas, breast, ovary, bladder,
kidney, and the nervous system [19,20]. Thus, we examined the
relationship between CARMA3 expression and EGFR status in
NSCLC. We found that EGFR was expressed in the cell
membrane and cytoplasmic. A significant correlation between
CARMA3 expression and expression of EGFR was observed
(P=0.009) in the NSCLC samples (Table 1 and Fig. 2A–D). To
determine whether the EGFR mutation is correlated with the
elevated CARMA3 expression, we investigated the relationship
between CARMA3 expression and EGFR mutation. We used an
EGFR mutation detection kit, and found 16 of 75 tumor samples
were positive for EGFR mutation (Table S2). Among the 16 cases,
87.5% exhibited positive CARMA3 expression, a much higher
rate compared to non-mutation cases (66.1%). We found that
86.67% EGFR positive mutation cases also exhibited positive
CARMA3 expression (Fig. 2E and F).
Figure 2. Examples of CAMRA3 and EGFR expression in NSCLC cases. Immunohistochemical staining for CARMA3 and EGFR in 2
representative NSCLC samples. One showed strong expression of CARMA3 (A) and strong EGFR expression (4006) (B). The other showed weak
expression of CARMA3(4006) (C) and weak EGFR expression(4006) (D). (E,F) Correlation of CARMA3 and EGFR expression in NSCLC samples with
EGFR mutation(4006).
doi:10.1371/journal.pone.0036903.g002
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Invasion
We first examined the expression of CARMA3 in several lung
cancer cell lines, as shown in Fig. 3B, H1299, A549, BE1 exhibited
high expression levels of CARMA3 whereas normal bronchial
epithelium (HBE) cells, LK2, and LH7 exhibited lower levels of
CARMA3 expression. SPC, H157, and H460 exhibited moderate
levels of CARMA3 expression.
We next employed an RNA interference approach to determine
whether CARMA3 and CBM complex (CARMA3-Bcl10-
MALT1) plays a role in cancer cell growth. The CARMA3 and
Bcl10 expression levels were unchanged upon transient transfec-
tion with the negative control siRNA, whereas CARMA3- or
Bcl10-specific siRNA significantly suppressed both mRNA as well
as protein expression levels in the H1299 and A549 cell lines
(Fig. 3A and Fig. S1). Next, we examined the cell growth rate.
With CARMA3 or Bcl10 siRNA, H1299 cells displayed reduced
growth rates compared to the negative control (Fig. 4A). Similar to
H1299 cells, we found that knockdown of CARMA3 or Bcl10 also
reduced the growth rate of A549 cells (Fig. 4A). We utilized an
independent method, colony formation assays, to validate the anti-
proliferative effects of CARMA3 or Bcl10 inhibition in lung
cancer cells. CARMA3- or Bcl10-targeting siRNAs led to a clear
reduction of the colony formation capacity of two tested lung
cancer cell lines compared to control siRNA-treated cells (Fig. 4B).
These loss-of-function studies demonstrated that the CARMA3
and CBM siRNAs could inhibit tumor cell proliferation compared
to irrelevant siNC. To further examine whether CARMA3 and
Bcl10 contribute to the invasive capabilities of non-small cell lung
cancer cells, we conducted matrigel invasion assays. Our results
demonstrated that the invasive capabilities of CARMA3- and
Bcl10-knockdown H1299 cancer cells were reduced compared to
the negative control cells (Fig. 5). Similarly, the knockdown of
CARMA3 or Bcl10 in A549 cells also reduced the invasive
capabilities of these cells (Fig. 5). Taken together, these results
demonstrate that CARMA3 and CBM complex are positive
regulators cell invasion.
CARMA3 Deletion Results in G1 Arrest and Growth
Inhibition of Lung Cancer Cells
Cell cycle analyses by fluorescence activated cell sorting (FACS)
were performed in cancer cells with or without CARMA3-
knockdown, and we found that the percentage of cells in the G1
phase was increased and cells in the S phase was decreased in cells
with CARMA3-knockdown compared to control cells (Fig.6 A).
These results suggest that CARMA3 deletion induces cell cycle
arrest at the G1/S boundary. To investigate the mechanism
underlying the induction of the cell cycle arrest, we tested the effect
of CARMA3-knockdown on Cyclin A, Cyclin D1, Cyclin D3,
CDK4, CDK6, P27, and P-Rb levels. As shown in (Fig.6 B),
Western blot analysis revealed that knockdown of CARMA3
decreased the protein levels of Cyclin D1, CDK4, CDK6, and P-
Rb but increased the levels of p27. Taken together, these results
Figure 3. CARMA3 depletion in H1299 and A549 cells. (A) Western blot analysis of CARMA3 expression in lung cancer cells transfected with
siRNA. (B) Relative CARMA3 expression profiles in a panel of human airway derived cell lines assessed by real-time PCR.
doi:10.1371/journal.pone.0036903.g003
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arrest in the G1 phase and suppresses lung cancer cell growth.
Suppression of CARMA3 Inhibits p-IkB and NF-kB
Activation
To determine whether CARMA3 mediates EGF-stimulated
NF-kB activation in lung cancer cells, we used H1299 and A549
cells. The cells that had undergone CARMA3 siRNA treatment
exhibited NF-kB inhibition in the presence or absence of EGF.
Similarly, our results demonstrated that siRNA-mediated Bcl10-
knockdown inhibited NF-kB luciferase expression (Fig.7 A). Our
study results clearly demonstrate the essential role of the
CARMA3-Bcl10-MALT1 signaling complex in EGF-induced
NF-kB activation in lung cancer cells. To further verify the role
of CARMA3 expression in EGF-induced NF-kB activation in
cancer cells, H1299 cells and A549 cells transduced with
CARMA3 siRNA were stimulated with EGF. We observed a
blockade in the ability of EGF to induce p-IkB concomitant with
Figure 4. CARMA3 depletion inhibits cancer cell proliferation. (A) Cell growth rate was determined by the CCK-8 assay, as described in
Section 2. The data are mean 6 SD of three independent experiments. (B) (Upper panel) H1299 and A549 cells transduced with siRNA for control,
CARMA3, or Bcl10 were subjected to colony formation assay. (lower panel) Histogram quantification. Error bars indicate 6SD (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0036903.g004
Figure 5. Knockdown of CARMA3 expression in H1299 and A549 cells inhibited cell invasion in a Boyden chamber assay. (Upper)
CARMA3 and Bcl10 siRNA treatment inhibited measurable cell invasion in both cell lines(2006). (Lower) The bar graph indicates the mean and
difference in cell number among the photographs, and the standard derivation was calculated from the average of cells in the 10 fields (**, P,0.01).
doi:10.1371/journal.pone.0036903.g005
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was not affected in CARMA3-deficient cells. Furthermore, the
CARMA3 knockdown did not impair EGF-induced phosphory-
lation of ERK (Fig.7 B). Taken together, our results demonstrate
that CARMA3, via IkB phosphorylation, mediates EGF-induced
NF-kB activation in lung cancer cells.
Discussion
In this study, we evaluated the expression pattern and biological
role of the novel scaffold protein CARMA3 in human NSCLC.
Our results demonstrated that CARMA3 protein expression in
lung cancer tissues is higher compared to corresponding normal
lung tissues. At the protein level, CARMA3 expression was
restricted to the cytoplasm in all samples. We found a significant
correlation between CARMA3 up-regulation and both TNM
stage and tumor status. In addition, we demonstrated that
Figure 6. Cell cycle distribution analysis. (A) (Upper) H1299 and A549 cells were treated with CARMA3-specific siRNA for 48 h. Next, the cells
were harvested and treated with RNase, and stained with PI. The cell cycle distribution was analyzed by flow cytometry. (Lower) The percentage of
cells in G1,S,G2 phase in histograms. (*p,0.05, **p,0.01, ***p,0.001) versus control group. The results are representative of at least three
independent experiments. (B) H1299 and A549 cells were treated with CARMA3-specific siRNA for 48 h. Cell lysates were subjected to
immunoblotting analysis using indicated antibodies.
doi:10.1371/journal.pone.0036903.g006
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rate of patients of nodal status N0 as well as EGFR status.
CARMA3 has been previously demonstrated to play a pivotal role
in EGFR induced activation of NF-kB [18]. EGFR mutation is
significantly correlated with elevated EGFR expression, its
downstream signaling, and clinical response to gefitinib therapy
[21]. Thus, we further examined the relationship between
CARMA3 expression and EGFR mutation. We found that the
expression of CARMA3 is significantly higher in EGFR mutation
cases compared to non-mutation cases. These results suggested
that CARMA3 may play an important role in EGFR-mutant lung
cancer. A recent report demonstrated that knockdown of several
components of the NF-kB pathway specifically enhanced cell
death induced by the EGFR TKI erlotinib in EGFR-mutant lung
cancer cells [22]. As overexpression of CARMA3 proteins induces
robust NF-kB activation [3,4], CARMA3 and NF-kB may serve as
potential companion drug targets along with EGFR in EGFR-
mutant lung cancer.
CARMA3 has been reported to promote ovarian cancer cell
progression [17], to increase human breast cancer cell growth and
Figure 7. CARMA3 is required for NF-kB activation in NSCLC. (A) H1299 and A549 cells were transfected with control or CARMA3-specific
siRNA for 24 h, then treated with NF-kB-luciferase and control Renilla reporter plasmids for 24 h. The cells were treated with or without EGF (100 ng/
ml) before harvest, and the resulting NF-kB induction was measured by calculating the luciferase/Renilla ratio. Data (mean_S.E.) are from at least three
separate determinations. (**p,0.01) (B) H1299 and A549 cells were transfected with an siRNA pool targeting CARMA3 for 48 h, then treated with EGF
(100 ng/ml) for the indicated periods of time. Total cell lysates were prepared from these cells and then subjected to immunoblotting analysis with
indicated antibodies.
doi:10.1371/journal.pone.0036903.g007
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(OSCC) [23]; CARMA3 also plays an important role in
atherogenesis [24] and NF-kB activation in airway epithelial cells
[25]. However, the functional role remains unclear. To elucidate
the biological function of CARMA3 in lung cancer, we employed
siRNA to knockdown CARMA3 expression in both A549 and
H1299 cell lines, which express high levels of CARMA3. We
observed impaired proliferation capacity in both A549 and H1299
cells after CARMA3 knockdown. Knockdown of Bcl10, which is
another component of the CBM complex, also impaired cell
proliferation. Thus, CARMA3 siRNA knockdown potentially
impairs malignant cell proliferation through the destruction of the
CARMA3-Bcl10-MALT1 complex. Most proliferative factors
influence cell growth by affecting cell cycle progression. In this
study, cell cycle analyses revealed that the percentage of cells in the
G1 phase was increased, whereas the percentage of cells in the S
phase was decreased in CARMA3-knockdown cells compared to
control cells. Knockdown of CARMA3 inhibited the G1 to S
transition in cell cycle progression, which suggests the role played
by CARMA3 in lung cancer cell proliferation. Cell cycle
progression is modulated by a number of molecules. To determine
the potential mechanism of CARMA3 concerning cell cycle
regulation, we examined the effect of CARMA3 knockdown on
cell cycle-related molecules. We analyzed the levels of cyclin A,
cyclin D1, cyclin D3, CDK4, CDK6, p-Rb, and P27 and found
that knockdown of CARMA3 decreased the protein levels of
Cyclin D1, CDK4, CDK6, and P-Rb but increased the levels of
p27. Cyclin D1, which drives the progression of cells into the
proliferative stages of the cell cycle, plays an important role in
tumorigenesis. The cyclin-D/CDK4, 6/pRB pathway has been
previously demonstrated to be altered in over 80% of human
tumors [26,27]. It is a key regulator of the critical G1 to S phase
transition of the cell cycle. During the G1 phase, pRB is
inactivated by sequential phosphorylation events mediated by
various cyclin dependant kinases (CDKs), leading to the release of
the E2F transcription factors, the activation of many genes, and
progression of the cell cycle [28]. The cyclin-dependent kinase
inhibitor p27 (also named Kip1) is a growth inhibitory protein that
blocks cell cycle progression at the G1/S transition [29]. Taken
together, these results indicate that CARMA3 controls the cell
cycle by regulating cyclin D1, CDK4, CDK6, p-Rb, and p27.
It has become increasingly clear that NF-kB signaling plays a
critical role in cancer development and progression [30–34]. Our
results further demonstrate a direct link between CARMA3 and
NF-kB activation. The change of cell cycle progression after
CARMA3 knockdown is potentially related to NF-kB. NF-kBi s
the subject of numerous pharmaceutical research studies as a
target for anti-cancer therapy. Blocking NF-kB potentially arrests
tumor cell proliferation and causes apoptosis, or enhances
sensitivity to the action of anti-tumor agents. The present study
demonstrated that CARMA3 knockdown inhibits NF-kB activa-
tion, thus blocking lung cancer progression and suggesting the
potential importance of this finding for novel cancer therapies.
Lung cancer is the leading cause of cancer deaths in the united
States and worldwide. The major form of lung cancer is NSCLC
[35].Despite advances in early detection and standard treatment,
NSCLC is often diagnosed at an advanced stage and has a poor
prognosis. Discover valuable biomarker for the detection of
NSCLC at an early stage can improve survival substantially.
Now, there are many potentially useful biomarkers for lung cancer
have been verified, such as CEA, CA-125, CYFRA 21-1, TPA
[35–39]. More and more novel potential biomarkers for lung
cancer have been discovered, such as SAA, DDH, EGFR, Mig-6
[40–43]. In this research we find CARMA3 as another potentially
useful biomarker for lung cancer. Identifications of biomarkers are
leading to more understanding of the molecular pathways involved
in lung cancer and help to reduce the suffering and loss of life
caused by the lethal disease [44].
In conclusion, our study demonstrated that CARMA3 is
overexpressed in NSCLC and correlates with lung cancer
progression. CARMA3 promotes lung cancer proliferation
through cell cycle regulation and NF-kB regulation.
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on the plot.
(JPG)
Table S1 Primer sequences.
(DOC)
Table S2 The expression of CARMA3 and EGFR in 16
NSCLC tissues with EGFR mutation.
(DOC)
Acknowledgments
We thank International Science Editing (Shannon Free zone - West,
Shannon, Co. Clare Ireland) for critical review of the manuscript.
Author Contributions
Conceived and designed the experiments: ZL XQ. Performed the
experiments: ZL LQ QD HL ZT. Analyzed the data: BH YX. Contributed
reagents/materials/analysis tools: WL LL EW. Wrote the paper: ZL QD.
References
1. Bertin J, Wang L, Guo Y, Jacobson MD, Poyet JL, et al. (2001) CARD11 and
CARD14 are novel caspase recruitment domain (CARD)/membrane-associated
guanylate kinase (MAGUK) family members that interact with BCL10 and
activate NF-kappa B. J Biol Chem 276: 11877–11882.
2. Gaide O, Martinon F, Micheau O, Bonnet D, Thome M, et al. (2001) Carma1,
a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation
and NF-kappaB activation. FEBS Lett 496: 121–127.
3. Wang L, Guo Y, Huang WJ, Ke X, Poyet JL, et al. (2001) Card10 is a novel
caspase recruitment domain/membrane-associated guanylate kinase family
CARMA3 in NSCLC
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e36903member that interacts with BCL10 and activates NF-kappa B. J Biol Chem 276:
21405–21409.
4. McAllister-Lucas LM, Inohara N, Lucas PC, Ruland J, Benito A, et al. (2001)
Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-
mediated NF-kappaB induction. J Biol Chem 276: 30589–30597.
5. Grabiner BC, Blonska M, Lin PC, You Y, Wang D, et al. (2007) CARMA3
deficiency abrogates G protein-coupled receptor-induced NF-{kappa}B activa-
tion. Genes Dev 21: 984–996.
6. McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, et al. (2007) CARMA3/
Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-
responsive inflammatory signaling in nonimmune cells. Proc Natl Acad
Sci U S A 104: 139–144.
7. Borthakur A, Bhattacharyya S, Alrefai WA, Tobacman JK, Ramaswamy K, et
al. (2010) Platelet-activating factor-induced NF-kappaB activation and IL-8
production in intestinal epithelial cells are Bcl10-dependent. Inflamm Bowel Dis
16: 593–603.
8. Marasco D, Stilo R, Sandomenico A, Monti SM, Tizzano B, et al. (2009)
Generation and functional characterization of a BCL10-inhibitory peptide that
represses NF-kappaB activation. Biochem J 422: 553–561.
9. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:
2195–2224.
10. Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:
203–208.
11. Lukiw WJ, Zhao Y, Cui JG (2008) An NF-kappaB-sensitive micro RNA-146a-
mediated inflammatory circuit in Alzheimer disease and in stressed human brain
cells. J Biol Chem 283: 31315–31322.
12. Singh MV, Kapoun A, Higgins L, Kutschke W, Thurman JM, et al. (2009)
Ca2+/calmodulin-dependent kinase II triggers cell membrane injury by
inducing complement factor B gene expression in the mouse heart. J Clin
Invest 119: 986–996.
13. Panzer U, Steinmetz OM, Turner JE, Meyer-Schwesinger C, von Ruffer C, et
al. (2009) Resolution of renal inflammation: a new role for NF-kappaB1 (p50) in
inflammatory kidney diseases. Am J Physiol Renal Physiol 297: F429–439.
14. Wang D, You Y, Lin PC, Xue L, Morris SW, et al. (2007) Bcl10 plays a critical
role in NF-kappaB activation induced by G protein-coupled receptors. Proc Natl
Acad Sci U S A 104: 145–150.
15. Klemm S, Zimmermann S, Peschel C, Mak TW, Ruland J (2007) Bcl10 and
Malt1 control lysophosphatidic acid-induced NF-kappaB activation and
cytokine production. Proc Natl Acad Sci U S A 104: 134–138.
16. Sun J, Lin X (2008) Beta-arrestin 2 is required for lysophosphatidic acid-induced
NF-kappaB activation. Proc Natl Acad Sci U S A 105: 17085–17090.
17. Mahanivong C, Chen HM, Yee SW, Pan ZK, Dong Z, et al. (2008) Protein
kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for
lysophosphatidic acid-induced urokinase plasminogen activator expression in
ovarian cancer cells. Oncogene 27: 1273–1280.
18. Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, et al. (2011) CARMA3 is crucial for
EGFR-Induced activation of NF-kappaB and tumor progression. Cancer Res
71: 2183–2192.
19. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, et al. (2009) The
juxtamembrane region of the EGF receptor functions as an activation domain.
Mol Cell 34: 641–651.
20. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R (2006) Epidermal growth
factor receptor - mediated signal transduction in the development and therapy of
gliomas. Clin Cancer Res 12: 7261–7270.
21. Sequist LV, Bell DW, Lynch TJ, Haber DA (2007) Molecular predictors of
response to epidermal growth factor receptor antagonists in non-small-cell lung
cancer. J Clin Oncol 25: 587–595.
22. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, et al. (2011) FAS and
NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR.
Nature 471: 523–526.
23. Rehman AO, Wang CY (2009) CXCL12/SDF-1 alpha activates NF-kappaB
and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex.
Int J Oral Sci 1: 105–118.
24. McAllister-Lucas LM, Jin X, Gu S, Siu K, McDonnell S, et al. (2010) The
CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent
vascular inflammation and atherogenesis. J Biol Chem 285: 25880–25884.
25. Medoff BD, Landry AL, Wittbold KA, Sandall BP, Derby MC, et al. (2009)
CARMA3 mediates lysophosphatidic acid-stimulated cytokine secretion by
bronchial epithelial cells. Am J Respir Cell Mol Biol 40: 286–294.
26. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control.
Nat Med 10: 789–799.
27. Nevins JR (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10:
699–703.
28. Giacinti C, Giordano A (2006) RB and cell cycle progression. Oncogene 25:
5220–5227.
29. Chu IM, Hengst L, Slingerland JM (2008) The Cdk inhibitor p27 in human
cancer: prognostic potential and relevance to anticancer therapy. Nat Rev
Cancer 8: 253–267.
30. Wichlinski L (1969) [New solvent system for thin-layer chromatography of ergot
alkaloids]. Acta Pol Pharm 26: 617–618.
31. Basseres DS, Baldwin AS (2006) Nuclear factor-kappaB and inhibitor of kappaB
kinase pathways in oncogenic initiation and progression. Oncogene 25:
6817–6830.
32. Karin M (2006) Nuclear factor-kappaB in cancer development and progression.
Nature 441: 431–436.
33. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related
inflammation. Nature 454: 436–444.
34. Prasad S, Ravindran J, Aggarwal BB (2010) NF-kappaB and cancer: how
intimate is this relationship. Mol Cell Biochem 336: 25–37.
35. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA
Cancer J Clin 62: 10–29.
36. Barlesi F, Gimenez C, Torre JP, Doddoli C, Mancini J, et al. (2004) Prognostic
value of combination of Cyfra 21–1, CEA and NSE in patients with advanced
non-small cell lung cancer. Respir Med 98: 357–362.
37. Pujol JL, Molinier O, Ebert W, Daures JP, Barlesi F, et al. (2004) CYFRA 21–1
is a prognostic determinant in non-small-cell lung cancer: results of a meta-
analysis in 2063 patients. Br J Cancer 90: 2097–2105.
38. Ando S, Kimura H, Iwai N, Yamamoto N, Iida T (2003) Positive reactions for
both Cyfra21–1 and CA125 indicate worst prognosis in non-small cell lung
cancer. Anticancer Res 23: 2869–2874.
39. Barak V, Goike H, Panaretakis KW, Einarsson R (2004) Clinical utility of
cytokeratins as tumor markers. Clin Biochem 37: 529–540.
40. Cho WC, Yip TT, Cheng WW, Au JS (2010) Serum amyloid A is elevated in the
serum of lung cancer patients with poor prognosis. Br J Cancer 102: 1731–1735.
41. Huang LJ, Chen SX, Huang Y, Luo WJ, Jiang HH, et al. (2006) Proteomics-
based identification of secreted protein dihydrodiol dehydrogenase as a novel
serum markers of non-small cell lung cancer. Lung Cancer 54: 87–94.
42. Nishio K, Arao T, Shimoyama T, Fujiwara Y, Tamura T, et al. (2005)
Translational studies for target-based drugs. Cancer Chemother Pharmacol 56
Suppl 1: 90–93.
43. Li Z, Dong Q, Wang Y, Qu L, Qiu X, et al. (2011) Downregulation of Mig-6 in
nonsmall-cell lung cancer is associated with EGFR signaling. Mol Carcinog.
44. Cho WC (2007) Potentially useful biomarkers for the diagnosis, treatment and
prognosis of lung cancer. Biomed Pharmacother 61: 515–519.
CARMA3 in NSCLC
PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e36903